Cognition Therapeutics
CGTX
Market cap $17.8M

0.4440 USD

-0.0187

4.04%

At close Nov 19, 4:00 PM EST

After hours

0.4459

+0.0019

0.43%

1 day

-4.04%

5 days

-26.00%

1 month

-5.87%

3 months

-41.42%

6 months

-78.86%

Year to date

-77.11%

1 year

-57.31%

5 years

-96.52%

10 years

-96.52%

About: Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.

Employees: 25

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,735 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

20% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 5

2.81% less ownership

Funds ownership: 13.26% [Q2] → 10.46% (-2.81%) [Q3]

15% less funds holding

Funds holding: 46 [Q2] → 39 (-7) [Q3]

44% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 16

78% less capital invested

Capital invested by funds: $8.82M [Q2] → $1.96M (-$6.86M) [Q3]

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$5

1,026%

upside

Avg. target

$9

1,927%

upside

High target

$11

2,377%

upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

Chardan Capital Daniil Gataulin 44% 1-year accuracy 11 / 25 met price target	2,377%upside $11	Buy Maintained	15 Nov 2024
HC Wainwright & Co. Raghuram Selvaraju 39% 1-year accuracy 115 / 294 met price target	1,026%upside $5	Buy Reiterated	4 Nov 2024
Chardan Capital Daniil Gataulin 44% 1-year accuracy 11 / 25 met price target	2,377%upside $11	Buy Maintained	31 Oct 2024

See Analyst Rankings

Financial journalist opinion

Based on 7 articles about CGTX published over the past 30 days

Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update

- CT1812 slowed cognitive decline by 95% in Alzheimer's disease patients with lower levels of plasma p-tau217 in a pre-specified analysis from Phase 2 SHINE study presented at CTAD -

Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update

Cognition Therapeutics to Present at Zacks SCR Life Sciences Investor Forum

PURCHASE, N.Y., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that President and CEO Lisa Ricciardi will present live at the virtual Zacks SCR Life Sciences Investor Forum on November 14, 2024. The Company's presentation will focus primarily on the results from the successful Phase 2 ‘SHINE' study of CT1812 in mild-to-moderate Alzheimer's disease. In addition, Ms. Ricciardi will provide an overview of the Company's ongoing clinical programs, including the Phase 2 ‘SHIMMER' study of CT1812 in dementia with Lewy bodies. Topline results from the ‘SHIMMER' study are expected by year-end 2024.

Cognition Therapeutics to Present at Zacks SCR Life Sciences Investor Forum

November's Small-Cap Treasures: 3 Stocks Poised for Growth

November is often a lucrative period for small-cap stock market investments. Historically, the S&P 500 and the small-cap-focused Russell 2000 have delivered strong returns during the November-April stretch.

November's Small-Cap Treasures: 3 Stocks Poised for Growth

Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD

- Patient characteristics are consistent with other DLB studies - PURCHASE, N.Y., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, presented participant baseline characteristics in the Phase 2 ‘SHIMMER' study of mild-to-moderate dementia with Lewy bodies (DLB).

Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD

Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD

- Results show CT1812 dramatically slowed cognitive decline in patients with lower levels of plasma p-tau217, an important biomarker of Alzheimer's disease pathology -

Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD

Analyses from Cognition's Positive Phase 2 ‘SHINE' Study of CT1812 in Mild-to-Moderate Alzheimer's Disease will be Presented in a Podium Presentation at CTAD

Presenting prespecified analysis of cognitive impact on plasma p-Tau 217 subgroups in ‘SHINE' Poster Presentation details b aseline characteristics from the signal-finding ‘SHIMMER' trial in DLB PURCHASE, N.Y., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced Michael Woodward, MD, FRACP, head of dementia research at Austin Health in Melbourne, Australia, will deliver an oral presentation at the Clinical Trials on Alzheimer's Disease (CTAD) conference, which is taking place October 29 - November 1, 2024, in Madrid, Spain.

Analyses from Cognition's Positive Phase 2 ‘SHINE' Study of CT1812 in Mild-to-Moderate Alzheimer's Disease will be Presented in a Podium Presentation at CTAD

Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB)

PURCHASE, N.Y., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, has released a new Conversations video podcast episode. The new episode, which has been launched during DLB Awareness Month, is titled “Executing Clinical Research in Dementia with Lewy Bodies (DLB).”

Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB)

Cognition Therapeutics Will Participate in the Roth Healthcare Opportunities Conference

PURCHASE, N.Y., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs to treat neurodegenerative disorders, today announced the Company's president and CEO Lisa Ricciardi will participate in a panel discussion titled Frontiers in Neuroscience during the 3rd Annual Roth Healthcare Opportunities Conference on October 9, 2024.

Cognition Therapeutics Will Participate in the Roth Healthcare Opportunities Conference

Cognition Therapeutics Supports Lewy Body Dementia Awareness Month and the Need for Improved Treatments for the Second Most Common Dementia

Cognition is advancing CT1812 in the Phase 2 ‘SHIMMER' clinical trial for the treatment of dementia with Lewy bodies with data readout in the fourth quarter of 2024 Cognition is advancing CT1812 in the Phase 2 ‘SHIMMER' clinical trial for the treatment of dementia with Lewy bodies with data readout in the fourth quarter of 2024

Cognition Therapeutics Supports Lewy Body Dementia Awareness Month and the Need for Improved Treatments for the Second Most Common Dementia

Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences

PURCHASE, N.Y., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, today announced the Company's president and CEO, Lisa Ricciardi will participate in two investor conferences in September.

Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences

See News Rankings

Charts implemented using Lightweight Charts™